 Connection
Susan Calcaterra to Methadone
This is a "connection" page, showing publications Susan Calcaterra has written about Methadone.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.215 |
|
|
|
-
Scherbak Y, Wehrer M, Jacknin G, Nelson A, Calcaterra S. Bridging the Gap: Empowering Pharmacists in Inpatient Injectable Naltrexone and Hospital-Dispensed Methadone Process Development. J Am Coll Clin Pharm. 2026 Mar; 9(3):e70186.
Score: 0.834
-
Calcaterra SL, Weimer MB, Grimm E, Scherbak Y, Abdel Galil R, Berger O, Bowman LA, Nesbit SA, Barany A, Buresh ME. Leveraging the 72-Hour Rule Change to Support Transition From Hospital to Opioid Treatment Program. JAMA Netw Open. 2025 11 03; 8(11):e2544996.
Score: 0.815
-
Calcaterra SL, Dafoe A, Tietbohl C, Thurman L, Bredenberg E. Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients. J Hosp Med. 2024 06; 19(6):460-467.
Score: 0.729
-
Calcaterra SL, Saunders S, Grimm E, Maki-Gianani E, Keniston A, Wold A, Bonaguidi A. In-Hospital Methadone Enrollment: a Novel Program to Facilitate Linkage from the Hospital to the Opioid Treatment Program for Vulnerable Patients with Opioid Use Disorder. J Gen Intern Med. 2024 02; 39(3):385-392.
Score: 0.703
-
Terasaki D, Smith C, Calcaterra SL. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol. Pharmacotherapy. 2019 10; 39(10):1023-1029.
Score: 0.530
-
Calcaterra SL, Bach P, Chadi A, Chadi N, Kimmel SD, Morford KL, Roy P, Samet JH. Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction. J Gen Intern Med. 2019 06; 34(6):1039-1042.
Score: 0.511
-
Calcaterra SL, Lockhart S, Natvig C, Mikulich-Gilbertson SK. Measuring the Impact of a Multi-Site In-Hospital Intervention for Opioid Use Disorder Treatment Provision: A Survey of Hospital-Based Clinicians. J Gen Intern Med. 2026 03; 41(4):1048-1057.
Score: 0.201
-
Calcaterra SL, Lockhart S, Natvig C, Mikulich S. Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage. J Hosp Med. 2023 10; 18(10):896-907.
Score: 0.175
-
Martin M, Englander H, Calcaterra SL. Things We Do for No Reason?: Avoiding methadone for opioid withdrawal. J Hosp Med. 2023 11; 18(11):1034-1037.
Score: 0.172
-
Calcaterra SL, Bottner R, Martin M, Englander H, Weinstein ZM, Weimer MB, Lambert E, Ronan MV, Huerta S, Zaman T, Ullal M, Peterkin AF, Torres-Lockhart K, Buresh M, O'Brien MT, Snyder H, Herzig SJ. Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. J Hosp Med. 2022 09; 17(9):679-692.
Score: 0.162
-
Calcaterra SL, Lockhart S, Callister C, Hoover K, Binswanger IA. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers. J Gen Intern Med. 2022 08; 37(11):2786-2794.
Score: 0.156
-
Calcaterra SL, Klie KA. Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis. Obstet Gynecol. 2020 04; 135(4):975.
Score: 0.138
-
Callister C, Porter S, Vatterott P, Keniston A, McBeth L, Mann S, Calcaterra SL, Limes J. The Impact of Completing X-Waiver Training and Clinical Addiction Exposure on Internal Medicine Residents Treating Patients With Opioid Use Disorder. Subst Use Addctn J. 2024 07; 45(3):356-366.
Score: 0.045
-
Terasaki D, Kulick B, Calcaterra S, Ray L. Phenobarbital for alcohol withdrawal in the context of the opioid epidemic: a neglected caveat. Addiction. 2023 07; 118(7):1198-1200.
Score: 0.043
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|